Expression of APP pathway mRNAs and proteins in Alzheimer’s disease

Aldea, 2002, Rapid detection of herpes simplex virus DNA in genital ulcers by real-time PCR using SYBR green I dye as the detection signal, J. Clin. Microbiol., 40, 1060, 10.1128/JCM.40.3.1060-1062.2002

Altschul, 1990, Basic local alignment search tool, J. Mol. Biol., 215, 403, 10.1016/S0022-2836(05)80360-2

Arelin, 2002, LRP and senile plaques in Alzheimer’s disease: colocalization with apolipoprotein E and with activated astrocytes, Brain Res. Mol. Brain Res., 104, 38, 10.1016/S0169-328X(02)00203-6

Blacker, 1998, The genetics of Alzheimer disease: current status and future prospects, Arch. Neurol., 55, 294, 10.1001/archneur.55.3.294

Braak, 1991, Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections, Brain Pathol., 1, 213, 10.1111/j.1750-3639.1991.tb00661.x

Cataldo, 2000, Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer’s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations, Am. J. Pathol., 157, 277, 10.1016/S0002-9440(10)64538-5

Fink, 1998, Real-time quantitative RT-PCR after laser-assisted cell picking, Nat. Med., 4, 1329, 10.1038/3327

Fukumoto, 1999, Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid beta peptides ending at A beta40 and A beta42, NeuroReport, 10, 2965, 10.1097/00001756-199909290-00017

Giulian, 1996, Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia, J. Neurosci., 16, 6021, 10.1523/JNEUROSCI.16-19-06021.1996

Gutala, 2004, The use of real-time PCR analysis in a gene expression study of Alzheimer’s disease post-mortem brains, J. Neurosci. Methods, 132, 101, 10.1016/j.jneumeth.2003.09.005

Haass, 1992, Amyloid beta-peptide is produced by cultured cells during normal metabolism, Nature, 359, 322, 10.1038/359322a0

Harrison, 1996, Amyloid precursor protein mRNAs in Alzheimer’s disease, Neurodegeneration, 5, 409, 10.1006/neur.1996.0055

Huse, 2000, Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer’s disease beta-secretase, J. Biol. Chem., 275, 33729, 10.1074/jbc.M004175200

Ingelsson, 2004, Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain, Neurology, 62, 925, 10.1212/01.WNL.0000115115.98960.37

Ingelsson, 2006, No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer’s disease brain, Acta Neuropathol. (Berl.), 112, 439, 10.1007/s00401-006-0095-3

Iwata, 2000, Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition, Nat. Med., 6, 143, 10.1038/77399

Iwata, 2001, Metabolic regulation of brain Abeta by neprilysin, Science, 292, 1550, 10.1126/science.1059946

Jacobsen, 1991, Quantitative measurement of alternatively spliced amyloid precursor protein mRNA expression in Alzheimer’s disease and normal brain by S1 nuclease protection analysis, Neurobiol. Aging, 12, 585, 10.1016/0197-4580(91)90090-7

Johnston, 1996, Quantification of APP and APLP2 mRNA in APOE genotyped Alzheimer’s disease brains, Brain Res. Mol. Brain Res., 43, 85, 10.1016/S0169-328X(96)00161-1

Kang, 2000, Modulation of amyloid beta-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor-related protein pathway, J. Clin. Invest., 106, 1159, 10.1172/JCI11013

Kim, 2000, Neuroendocrine-specific protein C, a marker of neuronal differentiation, is reduced in brain of patients with Down syndrome and Alzheimer’s disease, Biochem. Biophys. Res. Commun., 276, 329, 10.1006/bbrc.2000.3464

Kinoshita, 2001, Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein receptor-related protein and the amyloid precursor protein: role of the intracellular adapter protein Fe65, J. Neurosci., 21, 8354, 10.1523/JNEUROSCI.21-21-08354.2001

Koo, 1994, Evidence that production and release of amyloid beta-protein involves the endocytic pathway, J. Biol. Chem., 269, 17386, 10.1016/S0021-9258(17)32449-3

Lopes, 1994, Expression of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein is increased in reactive and neoplastic glial cells, FEBS Lett., 338, 301, 10.1016/0014-5793(94)80288-2

Matsui, 2006, Coodinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer Disease: relationship to formic acid extractable Ab42 levels, J. Neuropathol. Exp. Neurol., 65, 508, 10.1097/01.jnen.0000229238.05748.12

Miller, 1988, A simple salting out procedure for extracting DNA from human nucleated cells, Nucleic Acids Res., 16, 1215, 10.1093/nar/16.3.1215

Mirra, 1991, The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease, Neurology, 41, 479, 10.1212/WNL.41.4.479

Moir, 1998, Relative increase in Alzheimer’s disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain, J. Biol. Chem., 273, 5013, 10.1074/jbc.273.9.5013

Preece, 2004, Amyloid precursor protein mRNA levels in Alzheimer’s disease brain, Brain Res. Mol. Brain Res., 122, 1, 10.1016/j.molbrainres.2003.08.022

Rebeck, 1993, Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions, Neuron, 11, 575, 10.1016/0896-6273(93)90070-8

Rovelet-Lecrux, 2006, APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy, Nat. Genet., 38, 24, 10.1038/ng1718

Rumble, 1989, Amyloid A4 protein and its precursor in Down’s syndrome and Alzheimer’s disease, N. Engl. J. Med., 320, 1446, 10.1056/NEJM198906013202203

Selkoe, 1999, Translating cell biology into therapeutic advances in Alzheimer’s disease, Nature, 399, A23, 10.1038/399a023

Selkoe, 2001, Presenilin, Notch, and the genesis and treatment of Alzheimer’s disease, Proc. Natl. Acad. Sci. U. S. A., 98, 11039, 10.1073/pnas.211352598

Sinha, 1999, Purification and cloning of amyloid precursor protein beta-secretase from human brain, Nature, 402, 537, 10.1038/990114

Sola, 1993, Increased levels of the Kunitz protease inhibitor-containing beta APP mRNAs in rat brain following neurotoxic damage, Brain Res. Mol. Brain Res., 17, 41, 10.1016/0169-328X(93)90071-V

Soriano, 1999, Expression of beta-amyloid precursor protein-CD3gamma chimeras to demonstrate the selective generation of amyloid beta(1–40) and amyloid beta(1–42) peptides within secretory and endocytic compartments, J. Biol. Chem., 274, 32295, 10.1074/jbc.274.45.32295

Strittmatter, 1993, Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease, Proc. Natl. Acad. Sci. U. S. A., 90, 1977, 10.1073/pnas.90.5.1977

Suzuki, 1994, High expression on Kunitz-type protease inhibitor-containing substances in the cerebral vessels of patients with Down syndrome, Tohoku J. Exp. Med., 174, 181, 10.1620/tjem.174.181

Theuns, 2006, Promoter mutations that increase amyloid precursor–protein expression are associated with Alzheimer disease, Am. J. Hum. Genet., 78, 936, 10.1086/504044

Van Uden, 2000, LDL receptor-related protein (LRP) in Alzheimer’s disease: towards a unified theory of pathogenesis, Microsc. Res. Tech., 50, 268, 10.1002/1097-0029(20000815)50:4<268::AID-JEMT3>3.0.CO;2-1

Van Uden, 2000, A protective role of the low density lipoprotein receptor-related protein against amyloid beta-protein toxicity, J. Biol. Chem., 275, 30525, 10.1074/jbc.M001151200

Vassar, 1999, Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE, Science, 286, 735, 10.1126/science.286.5440.735

Wang, 1999, The levels of soluble versus insoluble brain Abeta distinguish Alzheimer’s disease from normal and pathologic aging, Exp. Neurol., 158, 328, 10.1006/exnr.1999.7085

Wenham, 1991, Apolipoprotein E genotyping by one-stage PCR, Lancet, 337, 1158, 10.1016/0140-6736(91)92823-K

Zhan, 1995, APP with Kunitz type protease inhibitor domain (KPI) correlates with neuritic plaque density but not with cortical synaptophysin immunoreactivity in Alzheimer’s disease and non-demented aged subjects: a multifactorial analysis, Clin. Neuropathol., 14, 142